ArticleFrontiers in immunology2025
Integrated analysis of myeloperoxidase in gastric health and cancer: associations with pepsinogen levels, immune regulation, and prognosis in a large healthy population-based and TCGA cohorts.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid-Soluble Signaling Molecular Model Predicts Prognosis and Immunotherapy Response in Gastric Cancer.Lipids · 2026Article
- The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer-From Pathophysiology to Therapeutic Impact.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myeloperoxidase (MPO) is a key enzyme involved in immune responses and oxidative stress, yet its roles in gastric physiology and gastric cancer remain incompletely understood. This study comprises two independent analyses: (1) to investigate the association between MPO and gastric mucosal injury markers (pepsinogen I, II, and PGR) in a large healthy population, and (2) to evaluate the prognostic significance and immune-regulatory mechanisms of MPO in gastric adenocarcinoma (GA). Methods: We analyzed data from 16,943 individuals in a healthy population-based cohort and 375 GA patients from The Cancer Genome Atlas (TCGA). In the healthy cohort, multivariate linear regression was used to evaluate associations between MPO and pepsinogen levels. In the GA cohort, survival analyses (OS, DSS, PFI) were conducted using Kaplan-Meier and Cox regression models. Gene expression analysis, functional enrichment (GO, KEGG, GSEA), and immune infiltration analysis (ssGSEA) were performed to explore MPO-related mechanisms in GA. Results: In the healthy cohort, MPO was inversely associated with PGR (β = -0.009, P < 0.0001) and PGI (β = -0.057, P < 0.0001). Subgroup and threshold effect analyses revealed non-linear associations and stronger effects among hypertensive individuals, smokers, and alcohol consumers. In the TCGA cohort, high MPO expression was an independent predictor of poor OS (HR = 2.781, P = 0.002) and DSS (HR = 3.667, P < 0.001). Functional analyses showed that MPO was associated with immune-related pathways and increased infiltration of macrophages (R = 0.379, P < 0.001) and dendritic cells (R = 0.377, P < 0.001). Conclusion: This study highlights the distinct roles of MPO in gastric mucosal injury and gastric cancer. In healthy individuals, MPO is associated with markers of gastric mucosal damage, while in GA patients, MPO serves as a prognostic biomarker linked to immune dysregulation. These findings suggest that MPO may be a potential target for monitoring or intervention in gastric mucosal injury and gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.